Difference between revisions of "Dasatinib (Sprycel)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 28: Line 28:
 
[[Category:Kinase inhibitors]]
 
[[Category:Kinase inhibitors]]
 
[[Category:Bcr-Abl inhibitors]]
 
[[Category:Bcr-Abl inhibitors]]
 +
[[Category:BTK inhibitors]]
 
[[Category:KIT inhibitors]]
 
[[Category:KIT inhibitors]]
 +
[[Category:LYN inhibitors]]
 
[[Category:SRC inhibitors]]
 
[[Category:SRC inhibitors]]
 +
[[Category:SYK inhibitors]]
 
[[Category:Acute lymphocytic leukemia medications]]
 
[[Category:Acute lymphocytic leukemia medications]]
 
[[Category:Chronic myelogenous leukemia medications]]
 
[[Category:Chronic myelogenous leukemia medications]]

Revision as of 20:43, 1 June 2014

General information

Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 6/28/06: FDA approved for the treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.

Also known as

BMS-354825

References